VivoSim's NAMkind Models Validated for Predicting ADC Toxicity and Side Effects

Tuesday, Mar 24, 2026 8:06 am ET1min read
VIVS--

VivoSim Labs has validated its NAMkind liver and intestine models to predict toxicity and side effects of antibody drug conjugates (ADCs). The models have shown close correlation with clinical results and can help screen out toxicities during lead candidate optimization or earlier stages, potentially resulting in greater success in the clinic with limited side effect profiles. NAMkind liver and small intestine toxicology services are now available globally.

VivoSim's NAMkind Models Validated for Predicting ADC Toxicity and Side Effects

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet